Proposed Diagnostic Criteria for Chronic Antibody-Mediated Rejection in Liver Allografts

American Journal of Transplantation

Volumn 16, Issue 2, 2016, Pages 603-614

  O'Leary, Jacqueline G ^a   Cai, J ^b   Freeman, R ^a   Banuelos, N ^b   Hart, B ^a   Johnson, M ^a   Jennings, L W ^a   Kaneku, H ^b   Terasaki, P I ^b   Klintmalm, G B ^a   Demetris, A J ^c  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b TERASAKI FOUNDATION LABORATORY   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ALLOANTIBODY; BILIRUBIN; DONOR SPECIFIC ALLOANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G4; TACROLIMUS; UNCLASSIFIED DRUG;

ADULT; ALLOGRAFT; ANTIBODY MEDIATED REJECTION; ARTICLE; CHRONIC ANTIBODY MEDIATED REJECTION SCORE; CHRONIC GRAFT REJECTION; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE CLASSIFICATION; FEMALE; FOLLOW UP; GRAFT FAILURE; GRAFT RECIPIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; LIVER BIOPSY; LIVER FIBROSIS; LIVER FUNCTION TEST; LIVER GRAFT REJECTION; LIVER INJURY; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; UPREGULATION; ADVERSE EFFECTS; BLOOD; CASE CONTROL STUDY; END STAGE LIVER DISEASE; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOLOGY; POSTOPERATIVE COMPLICATION; PROGNOSIS; RISK FACTOR;

ALLOGRAFTS; CASE-CONTROL STUDIES; END STAGE LIVER DISEASE; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; ISOANTIBODIES; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84957971220     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.13476     Document Type: Article

References (59)

1. Smith RN, Colvin RB., Chronic alloantibody mediated rejection. Semin Immunol 2012; 24: 115-121.
2. Kobashigawa J, Crespo-Leiro MG, Ensminger SM, et al., Report from a consensus conference on antibody-mediated rejection in heart transplantation. J Heart Lung Transplant 2011; 30: 252-269.
3. O'Leary JG, Demetris AJ, Friedman LS, et al., The role of donor-specific HLA alloantibodies in liver transplantation. Am J Transplant 2014; 14: 779-787.
4. Manez R, Kelly RH, Kobayashi M, et al., Immunoglobulin G lymphocytotoxic antibodies in clinical liver transplantation: Studies toward further defining their significance. Hepatology 1995; 21: 1345-1352.
5. Takaya S, Duquesnoy R, Iwaki Y, et al., Positive crossmatch in primary human liver allografts under cyclosporine or FK 506 therapy. Transplant Proc 1991; 23 (Pt 1): 396-399.
6. Takaya S, Bronsther O, Iwaki Y, et al., The adverse impact on liver transplantation of using positive cytotoxic crossmatch donors. Transplantation 1992; 53: 400-406.
7. Manez R, Kobayashi M, Takaya S, et al., Humoral rejection associated with antidonor lymphocytotoxic antibodies following liver transplantation. Transplant Proc 1993; 25 (Pt 2): 888-890.
8. Lunz J, Ruppert KM, Cajaiba MM, et al., Re-examination of the lymphocytotoxic crossmatch in liver transplantation: Can C4d stains help in monitoring ? Am J Transplant 2012; 12: 171-182.
9. O'Leary JG, Kaneku H, Jennings LW, et al., Preformed class II donor-specific antibodies are associated with an increased risk of early rejection after liver transplantation. Liver Transpl 2013; 19: 973-980.
10. Starzl TE, Demetris AJ, Todo S, et al., Evidence for hyperacute rejection of human liver grafts: The case of the canary kidneys. Clin Transplant 1989; 3: 37-45.
11. Kozlowski T, Rubinas T, Nickeleit V, et al., Liver allograft antibody-mediated rejection with demonstration of sinusoidal C4d staining and circulating donor-specific antibodies. Liver Transpl 2011; 17: 357-368.
12. Demetris AJ, Murase N, Nakamura K, et al., Immunopathology of antibodies as effectors of orthotopic liver allograft rejection. Semin Liver Dis 1992; 12: 51-59.
13. Demetris AJ, Nakamura K, Yagihashi A, et al., A clinicopathological study of human liver allograft recipients harboring preformed IgG lymphocytotoxic antibodies. Hepatology 1992; 16: 671-681.
14. Kozlowski T, Andreoni K, Schmitz J, Hayashi PH, Nickeleit V., Sinusoidal C4d deposits in liver allografts indicate an antibody-mediated response: Diagnostic considerations in the evaluation of liver allografts. Liver Transpl 2012; 18: 641-658.
15. O'Leary JG, Michelle Shiller S, Bellamy C, et al., Acute liver allograft antibody-mediated rejection: An inter-institutional study of significant histopathological features. Liver Transpl 2014; 20: 1244-1255.
16. Paterno F, Shiller M, Tillery G, et al., Bortezomib for acute antibody-mediated rejection in liver transplantation. Am J Transplant 2012; 12: 2526-2531.
17. O'Leary JG, Kaneku H, Demetris AJ, et al., Antibody-mediated rejection as a contributor to previously unexplained early liver allograft loss. Liver Transpl 2014; 20: 218-227.
18. Del Bello A, Congy-Jolivet N, Muscari F, et al., Prevalence incidence and risk factors for donor-specific anti-HLA antibodies in maintenance liver transplant patients. Am J Transplant 2014; 14: 867-875.
19. Taner T, Gandhi MJ, Sanderson SO, et al., Prevalence, course and impact of HLA donor-specific antibodies in liver transplantation in the first year. Am J Transplant 2012; 12: 1504-1510.
20. Musat AI, Pigott CM, Ellis TM, et al., Pretransplant donor-specific anti-HLA antibodies as predictors of early allograft rejection in ABO-compatible liver transplantation. Liver Transpl 2013; 19: 1132-1141.
21. Kaneku H, O'Leary JG, Banuelos N, et al., De novo donor-specific HLA antibodies decrease patient and graft survival in liver transplant recipients. Am J Transplant 2013; 13: 1541-1548.
22. Girnita A, Mazariegos GV, Castellaneta A, et al., Liver transplant recipients weaned off immunosuppression lack circulating donor-specific antibodies. Hum Immunol 2010; 71: 274-276.
23. Feng S, Demetris AJ, Ekong U, et al., Serum and tissue DSA subclass, stellate and endothelial phenotype monitoring in ITN029ST tolerance pediatric liver transplant recipients over 5+ years of follow-up. Abstract presented at: International Liver Transplant Society Meeting; 2014; London.
24. Feng S, Ekong UD, Lobritto SJ, et al., Complete immunosuppression withdrawal and subsequent allograft function among pediatric recipients of parental living donor liver transplants. JAMA 2012; 307: 283-293.
25. O'Leary JG, Kaneku H, Banuelos N, Jennings LW, Klintmalm GB, Terasaki PI., Impact of IgG3 subclass and C1q-fixing donor-specific HLA alloantibodies on rejection and survival in liver transplantation. Am J Transplant. 2015 15: 1003-1013.
26. O'Leary JG, Kaneku H, Jennings L, Susskind BM, Terasaki PI, Klintmalm GB., Donor-specific alloantibodies are associated with fibrosis progression after liver transplantation in hepatitis C virus-infected patients. Liver Transpl 2014; 20: 655-663.
27. Markiewicz-Kijewska M, Kalicinski P, Kluge P, et al., Immunological factors and liver fibrosis in pediatric liver transplant recipients. Ann Transplant 2015; 20: 279-284.
28. Miyagawa-Hayashino A, Yoshizawa A, Uchida Y, et al., Progressive graft fibrosis and donor-specific human leukocyte antigen antibodies in pediatric late liver allografts. Liver Transpl 2012; 18: 1333-1342.
29. Salah A, Fujimoto M, Yoshizawa A, et al., Application of complement component 4d immunohistochemistry to ABO-compatible and ABO-incompatible liver transplantation. Liver Transpl 2014; 20: 200-209.
30. Egawa H, Miyagawa-Hayashino A, Haga H, et al., Non-inflammatory centrilobular sinusoidal fibrosis in pediatric liver transplant recipients under tacrolimus withdrawal. Hepatol Res 2012; 42: 895-903.
31. Ohe H, Uchida Y, Yoshizawa A, et al., Association of anti-human leukocyte antigen and anti-angiotensin II type 1 receptor antibodies with liver allograft fibrosis after immunosuppression withdrawal. Transplantation 2014; 98: 1105-1111.
32. Iacob S, Cicinnati VR, Lindemann M, et al., Donor-specific anti-HLA antibodies and endothelial C4d deposition-Association with chronic liver allograft failure. Transplantation 2015; 99: 1864-1875.
33. O'Leary JG, Kaneku H, Susskind BM, et al., High mean fluorescence intensity donor-specific anti-HLA antibodies associated with chronic rejection postliver transplant. Am J Transplant 2011; 11: 1868-1876.
34. Grabhorn E, Binder TM, Obrecht D, et al., Long-term clinical relevance of de novo donor-specific antibodies after pediatric liver transplantation. Transplantation 2015; 99: 1876-1881.
35. Tchao N, Sayre P, Feng S, et al., Long-term immunosuppression management in OLT recipients. Am J Transplant 2007; 7: 550.
36. Kaneku H, O'Leary JG, Taniguchi M, Susskind BM, Terasaki PI, Klintmalm GB., Donor-specific human leukocyte antigen antibodies of the immunoglobulin G3 subclass are associated with chronic rejection and graft loss after liver transplantation. Liver Transpl 2012; 18: 984-992.
37. Venturi C, Sempoux C, Bueno J, et al., Novel histologic scoring system for long-term allograft fibrosis after liver transplantation in children. Am J Transplant 2012; 12: 2986-2996.
38. Demetris AJ, Isse K., Tissue biopsy monitoring of operational tolerance in liver allograft recipients. Curr Opin Organ Transplant 2013; 18: 345-353.
39. Muczynski KA, Ekle DM, Coder DM, Anderson SK., Normal human kidney HLA-DR-expressing renal microvascular endothelial cells: Characterization, isolation, and regulation of MHC class II expression. J Am Soc Nephrol 2003; 14: 1336-1348.
40. Page C, Rose M, Yacoub M, Pigott R., Antigenic heterogeneity of vascular endothelium. Am J Pathol 1992; 141: 673-683.
41. Benitez C, Londono MC, Miquel R, et al., Prospective multicenter clinical trial of immunosuppressive drug withdrawal in stable adult liver transplant recipients. Hepatology 2013; 58: 1824-1835.
42. Yamada H, Kondou H, Kimura T, et al., Humoral immunity is involved in the development of pericentral fibrosis after pediatric live donor liver transplantation. Pediatr Transplant 2012; 16: 858-865.
43. Giral M, Foucher Y, Dufay A, et al., Pretransplant sensitization against angiotensin II type 1 receptor is a risk factor for acute rejection and graft loss. Am J Transplant 2013; 13: 2567-2576.
44. Taniguchi M, Rebellato LM, Cai J, et al., Higher risk of kidney graft failure in the presence of anti-angiotensin II type-1 receptor antibodies. Am J Transplant 2013; 13: 2577-2589.
45. Mengel M, Sis B, Haas M, et al., Banff 2011 Meeting report: New concepts in antibody-mediated rejection. Am J Transplant 2012; 12: 563-570.
46. Steinhoff G, Wonigeit K, Pichlmayr R., Analysis of sequential changes in major histocompatibility complex expression in human liver grafts after transplantation. Transplantation 1988; 45: 394-401.
47. Ballardini G, Bianchi FB, Mirakian R, Fallani M, Pisi E, Bottazzo GF., HLA-A,B,C, HLA-D/DR and HLA-D/DQ expression on unfixed liver biopsy sections from patients with chronic liver disease. Clin Exp Immunol 1987; 70: 35-46.
48. Barbatis C, Kelly P, Greveson J, Heryet A, McGee JO., Immunocytochemical analysis of HLA class II (DR) antigens in liver disease in man. J Clin Pathol 1987; 40: 879-884.
49. Gouw AS, Huitema S, Grond J, et al., Early induction of MHC antigens in human liver grafts. An immunohistologic study. Am J Pathol 1988; 133: 82-94.
50. O'Leary JG, Gebel HM, Ruiz R, et al., Class II alloantibody and mortality in simultaneous liver-kidney transplantation. Am J Transplant 2013; 13: 954-960.
51. Dar W, Agarwal A, Watkins C, et al., Donor-directed MHC class I antibody is preferentially cleared from sensitized recipients of combined liver/kidney transplants. Am J Transplant 2011; 11: 841-847.
52. Oguma S, Belle S, Starzl TE, Demetris AJ., A histometric analysis of chronically rejected human liver allografts: Insights into the mechanisms of bile duct loss: Direct immunologic and ischemic factors. Hepatology 1989; 9: 204-209.
53. Takemura M, Oguma S, Mori S, et al., Peribiliary vascular diseases in rejected livers; computer-aided three-dimensional reconstruction and morphometry. Transplant Proc 1991; 23 (Pt 2): 1409-1412.
54. Matsumoto Y, McCaughan GW, Painter DM, Bishop GA., Evidence that portal tract microvascular destruction precedes bile duct loss in human liver allograft rejection. Transplantation 1993; 56: 69-75.
55. Dorling A., Transplant accommodation-Are the lessons learned from xenotransplantation pertinent for clinical allotransplantation ? Am J Transplant 2012; 12: 545-553.
56. Sher LS, Cosenza CA, Michel J, et al., Efficacy of tacrolimus as rescue therapy for chronic rejection in orthotopic liver transplantation: A report of the U.S. Multicenter Liver Study Group. Transplantation 1997; 64: 258-263.
57. O'Leary JG, Samaniego M, Barrio MC, et al., The influence of immunosuppressive agents on the risk of de novo donor-specific HLA antibody production in solid organ transplant recipients. Transplantation. 2015; In press.
58. O'Leary JG, Kaneku H, Banuelos N, Jennings LW, Klintmalm GB, PI T,. Impact of IgG3 subclass and C1q-fixing donor-specific HLA antibodies on rejection and survival in liver transplantation. Am J Transplant 2014; 15: 1003-1013.
59. Lee SJ, Qin H, Benveniste EN,. The IFN-gamma-induced transcriptional program of the CIITA gene is inhibited by statins. Eur J Immunol 2008; 38: 2325-2336.